HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Wednesday, 6 August 2014

ScHARR's 4th Annual Pemberton Lecture

Image by booleansplit via Flickr CC BY 2.0 
We are fortunate to have Professor Trish Greenhalgh, Professor of Primary Health Care and Dean for Research Impact at Barts and the London School of Medicine and Dentistry, to deliver ScHARR's fourth Pemberton Lecture at 17:00 on Tuesday, 9 September 2014. Professor Greenhalgh will speak on the topic: ''Research impact: defining it, measuring it, maximising it, questioning it'.

Professor Greenhalgh says:

"Both in the UK and more widely, the higher education sector is under pressure from government to demonstrate that it makes a difference. That aside, few of us want to be the kind of academic that sits in an ivory tower thinking clever thoughts while Rome burns below. As Karl Marx said, many academics only interpret the world, but the true purpose of scholarship is to change it. The 'impact agenda' thus contains two goals that may occasionally be in tension with one another. The first is to demonstrate impact as defined by a relatively narrow set of government-driven criteria and metrics (most notably in the UK, the 'Impact' section of the Research Excellence Framework). There is much emphasis in policy circles, for example, on the need for medical schools to build links with industry with a view to generating 'health and wealth' (that is, improving survival or quality of life while also saving money and boosting business for our national industries). The second goal, more in line with the vision of engaged scholarship articulated by Marx, is to align the research agenda with such things as community-campus partnerships and a commitment to social justice.

Whilst it is easy to be cynical about the colonisation of academia by commercial interests, many universities now boast fruitful industry collaborations that have not only supported the development of new drugs, devices and technologies (and, in a few cases, led to measurable economic benefit for the university) but which have also accelerated the uptake and use of innovations for societal benefit. Nevertheless, much of the impact from biomedical research to date has been through a wide range of non-commercial partnerships with clinical provider organisations, national policymakers, councils, schools, faith groups, third-sector organisations and citizens. In short, 'impact' is much more than commercial spin-offs.”

As the first 'Dean for Research Impact' appointed by a UK higher education institution, Professor Greenhalgh will summarise prevailing national and international debates about what research impact is; how it should be measured; how to balance the potentially conflicting agendas of 'economic' and 'societal' impact; and how to build capacity at all levels for delivering on both these agendas." 

You are invited to attend what should be a stimulating lecture on impact and to stay for the following wine reception. Admission to the lecture is free by ticket only. Please would you confirm your attendance by 1 September 2014 at the latest using the on-line registration form.